We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.

FOR PREVIEW ONLY (Print)

Julia Ljubimova, MD, PhD

Director, Nanomedicine Research Center in the Maxine Dunitz Neurosurgical Research Institute

Professor, Biomedical Sciences

Professor, Neurosurgery

Email:

ljubimovaj@cshs.org

Research Office:

Phone:

310-423-0834

Julia Ljubimova, MD, PhD

Director, Nanomedicine Research Center in the Maxine Dunitz Neurosurgical Research Institute

Professor, Biomedical Sciences

Professor, Neurosurgery

Julia Ljubimova, MD, PhD, is director of the Nanomedicine Research Center in the Cedars-Sinai Department of Neurosurgery. Her main interests are differential cancer gene expression as a tool for finding novel and early markers of cancer growth and development, and the design of new nanomedicine drugs against tumor targets. The Nanomedicine Research Center has developed several nanobioconjugates that selectively target brain and breast cancer and thus could have less dose-limiting toxicity than existing therapies. Ljubimova joined the faculty at Cedars-Sinai to direct studies combining basic cancer and translational research for discovering specific tumor markers. One of the novel markers, the structural tumor vessel wall protein laminin-411, is in a clinical trial as a prognostic and diagnostic marker for human glial tumor progression. This discovery led to the development of new technologies for drug delivery and engineering of the new class of imaging and anti-cancer nanomedicines for MRI cancer-specific diagnostics and inhibition of tumor-specific molecular targets. Ljubimova also is studying the influence of air pollution on activation of molecular markers in the brain that can lead to differential expression of genes that play an important role in tumorigenesis. Her studies have been published in peer-reviewed journals including Cancer Research, Cell, The American Journal of Pathology, Angiogenesis, Nanomedicine and Proceedings of the National Academy of Sciences. Her research is funded by grants from the National Institutes of Health along with state and private funds. Current investigations include the drug delivery system passing through the blood-brain barrier to deliver drugs to brain tumors and having the ability to block several cancer-specific tumor markers by using biodegradable nanoconjugate for brain and breast tumors; cancer-specific drug targeting; and development of nano-imaging agents for the brain tumor "virtual biopsy" using MRI.

  • Medical School: National Academy of Sciences of Ukraine, 1986
  • Post Doctorate: Baylor College of Medicine, 1990
  • Chair of Organizing Committee, 3rd International Nanomedicine for Imaging and Treatment Conference, 2015
  • Plenary Session Chair III and Speaker, Challenges and Opportunities for Nanotechnology in Cancer at NCI Alliance for Nanotechnology in Cancer Program Principal Investigators meeting. Bethesda, Maryland, 2013
  • Member of Organizing Committee, 3rd International Conference on Nanotek & Expo. Las Vegas, Neveda, 2013
  • Director of Organizing Committee, 2nd International Nanomedicine for Imaging and Treatment Conference. Los Angeles,California, 2013
  • Invited Speaker, 12th International Conference Polymers for Advance Technologies – "Polymeric Nanobioconjugates for Cancer Treatment". Berlin, Germany, 2012
  • Invited Speaker, UCLA-USC-Caltech Nanotechnology & Nanomedicine Symposium: Nanotechnology Innovations in Cancer, Infectious Diseases, and Regenerative Medicine – "Dual Modality Nanoconjugates for Virtual Brain Tumor Biopsy", 2013
  • Invited Speaker, Asia ARVO: Innovating and Converging Technologies in Vision Research – "Nanodrug Design for Treatment Safety and Efficacy". New Delhi, India, 2013
  • Plenary Session Chair, XX Helsinki Drug Research Congress, 2011

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Patil R, Ljubimov AV, Gangalum PR, Ding H, Portilla-Arias J, Wagner S, Inoue S, Konda B, Rekechenetskiy A, Chesnokova A, Markman JL, Ljubimov VA, Li D, Prasad RS, Black KL, Holler E, Ljubimova JY. MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates. ACS Nano. 2015;9(5):5594-5608.
  • Hsu BB, Jamieson K, Holler E, Ljubimova JY, Hammond PT. Ordered and kinetically discrete sequential protein release from biodegradable thin films. Angew Chem Int Ed Engl. 2014;53(31):8093-8098.
  • Ljubimova JY, Ding H, Portilla-Arias J, Patil R, Gangalum PR, Chesnokova A, Inoue S, Rekechenetskiy A, Nassoura T, Black KL, et al. Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine? J Vis Exp. 2014;13(88).
  • Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum PR, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black KL, Holler E, Penichet ML, Ljubimova JY. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release. 2013;171(3):322-329.
  • Ding H, Inoue S, Ljubimov AV, Patil R, Portilla-Arias J, Hu J, Konda B, Wawrowsky KA, Fujita M, Karabalin N, Black KL, Holler E, Ljubimova JY. Inhibition of brain tumor growth by intravenous poly(β-L-malic acid) nanobioconjugate with pH-dependent drug release. Proc Natl Acad Sci USA. 2010;107(42):18143-18148.
  • Ljubimova JY, Black KL, Ljubimov AV, Holler E. Biodegradable multitargeting nanoconjugates for drug delivery. In: Multifunctional Pharmaceutical Nanocarriers. 2008;233-262.

Show moreShow less